$4.340
+0.243 (+5.60%)收盘时
FOCL 资讯
FOCL 事件
FocalTherics Reports Q3 Revenue of $9.83M
Reports Q3 revenue $9.83M, consensus $11.51M. "We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France," said Ryan Rhodes, CEO of FocalTherics. "U.S. procedure volumes accelerated year-over-year to 32% for the third quarter of 2026, compared to 15% in 2025. Driven by our sustained commercial traction, accelerating technology adoption, and our focus on our HIFU opportunity, we remain highly confident in our growth strategy and on the opportunity ahead as we close out the year."
Company Narrows 2026 Revenue Guidance to $52M
Consensus $52M. The company said, "We are narrowing our full-year 2026 revenue guidance to be in the range of $50.0 to $52.0 million, representing 34% to 39% growth over 2025, from the prior range of $50.0 to $54.0 million."
Major Averages Broadly Lower Near Noon
The major averages were broadly lower near noon as investors continue to balance easing inflation pressures and strong corporate earnings against renewed geopolitical risks.The inflation backdrop remains supportive for equities. July CPI and PPI both came in softer than expected, reducing concerns that the Federal Reserve will need to raise interest rates at its September meeting. PPI was unchanged in July after declining 0.1% in June, while the latest CPI data showed inflation continuing to moderate. The market is increasingly focused on whether the combination of cooling inflation and a weakening labor market will give the Fed room to ease policy later this year.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applied Materialsreportedand provided upbeat Q4 earnings guidanceU.S. President Donald Trumpand their parts and componentsRedditwasAvalonBayin the S&P 500 at the August 18 openTeslaredesigned Roadster may have flying capabilities,OpenAI is on pace to generate annualized revenue of over $40B based on its present performance,2. WALL STREET CALLS:New StreetMicronto Buy, sees multi-trillion market cap by 2030SanDiskwith a raised Overweight rating at JPMorganCiscoto Hold at HSBCWayfairto Outperform at BernsteinFox Corp.to Overweight at Wells Fargo and JPMorgan3. AROUND THE WEB:Nokiais closing its research and development unit in Hangzhou, China, and cutting 1,600 jobs, Helsingin saysCharter Communicationsreceived final approval from California regulators to buy Cox Communications for $21.9B, WSJ reportsGoldman Sachsis courting investors to participate in Nvidia's$500B AI infrastructure financing initiative, leveraging its longstanding Nvidia relationship to secure a key role in mobilizing capital for the AI buildout, Reuters saysBPand UAE-based XRG have secured an exploration and production license for Venezuela's Loran offshore gas field, which holds an estimated 4 trillion cubic feet of recoverable gas and straddles the Venezuela-Trinidad and Tobago maritime boundary, WSJ reportsApplehas trained a large language model in partnership with Alibabafor China's market, Reuters reports4. MOVERS:Capricor Therapeuticsgains afterand announcing the FDA is "willing" to review the company's BLA amendment for its HOPE-3 studyValnevaincreases in New York after announcing with Pfizerthat the EMA has validated theIntermexhigher after providing an update on itsfor Western Union'spending acquisition of the companyKinderCarefalls afterand cutting its guidance for FY26Merlinand York Space Systemslower in New York after5. EARNINGS/GUIDANCE:Heartflowand raised its outlook for FY26Midera Food, with CEO Mark Salman commenting, "We saw continued momentum in the second quarter, with orders up 16% and the backlog reaching $446 million"Teamsharesand backed its outlook for FY26DLocal, with CEO Pedro Arnt commenting, "TPV growth has remained above 50% year-over-year for seven consecutive quarters, with the last three quarters at or above 70%"FocalThericsand backed its outlook for FY26INDEXES:Near midday, the Dow was down 0.19%, or 103.36, to 53,736.63, the Nasdaq was down 0.48%, or 128.01, to 26,675.02, and the S&P 500 was down 0.21%, or 16.73, to 7,782.26.
FocalTherics Q2 Revenue at $13.2M, Below Expectations
Reports Q2 revenue $13.2M, consensus $15.08M. "We continue to demonstrate commercial success with our strongest second quarter ever, reflecting the growing strength of our core business and further supporting the strategic shift to Focal Therapy with our corporate rebranding to FocalTherics," said Ryan Rhodes, CEO of FocalTherics. "Along with strong commercial momentum, we are also pleased with the developing progress of the endometriosis commercial launch in Europe and look forward to establishing additional Focal One programs to increase access to an important, non-surgical option for women with this highly debilitating condition. In addition, with expected proceeds from our ongoing capital raise, we will continue to accelerate commercial adoption in the global prostate cancer market while leveraging our multi-indication Focal One platform to grow market opportunities in treating endometriosis and expanding into benign prostatic hyperplasia or BPH. We will also continue to invest in our innovation and product development initiatives driving advances in AI-assisted treatments, FocalConnect telecollaboration technology, and integrating histotripsy together with HIFU on our Focal One platform."
Company Announces ESWL and Distribution Segments as Discontinued Operations
The company said, "During the second quarter of 2026, the ESWL and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements - Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company's operations and financial results. Accordingly, the Company's unaudited financial results as of and for the three and six months ended June 30, 2026 reflect the Company's ESWL and Distribution operating segments as discontinued operations."
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。




